Cost-Effectiveness Analysis of Dabigatran, Rivaroxaban and Warfarin in the Prevention of Stroke in Patients with Atrial Fibrillation in China

Abstract Background and objective: To evaluate the cost-effectiveness of new anticoagulants and warfarin in the prevention of stroke in Chinese patients with atrial fibrillation. Methods: the Markov model was constructed to compare the quality of life years of patients with dabigatran 110 and 150mg, twice a day, rivaroxaban 20mg, once a day, warfarin 3-6mg, once a day drug cost, and the cost of examination after taking the drug and the incremental cost of other treatments. Results: the total cost of warfarin, rivaroxaban, dabigatran for 110mg bid and 150mg bid was 37806.08 yuan, 210977.4 yuan, 167906.1 yuan and 244050.1 yuan, respectively. The QALYs available were 11.07 years, 15.46 years, 12.4 years and 15 years, respectively. The cost-effectiveness analysis of three new oral anticoagulants and warfarin showed that rivaroxaban compared with warfarin The incremental cost effectiveness ratio (ICER) is 39446.77 yuan / QALY, which is the advantage scheme and warfarin is the expansion disadvantage scheme. Conclusion: In Chinese patients with AF, although warfarin is cheaper, rivaroxaban has a better cost-effectiveness advantage from an economic point of view.